But even as Ozempic enters India, there is a growing sense globally that Novo may have already lost the obesity drug war to Mounjaro, Eli Lilly’s blockbuster that has become India’s top-selling drug by value in the seven months since its launch. Depending on the weekly dose, Mounjaro costs roughly Rs 14,000-Rs 17,500 per month.